---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-017624"
form_type: "8-K"
ticker: "CYDY"
cik: "0001175680"
company_name: "CytoDyn Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T19:09:17.171509+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CytoDyn remains under FDA clinical hold; seeks authorized share increase for viability

## Summary
- FDA partial clinical hold still unresolved; comprehensive resubmission made, outcome pending.
- Workforce reductions implemented; cash burn rate and operating expenses cut to conserve resources.
- Amarex arbitration final hearing scheduled for August 12, 2024; Sidley Austin LLP retained.
- Developed MASH clinical trial protocol and AI partnership for longer-acting therapeutic.
- Shareholders asked to approve increase in authorized common shares at Nov 9 annual meeting.

## SEC filing metadata
- accession: 0001558370-23-017624
- form_type: 8-K
- ticker: CYDY
- cik: 0001175680
- company_name: CytoDyn Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175680/000155837023017624/0001558370-23-017624-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175680/000155837023017624/cydy-20231103x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-017624
- JSON: https://secwatch.observer/filing/0001558370-23-017624.json
- Plain text: https://secwatch.observer/filing/0001558370-23-017624.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.